Biosynth to Offer Complex Chemistry Solutions at Greater Scales Following Acquisition of VIO Chemicals
Expansion of capacity for reliable, sustainable, and flexible manufacturing solutions at any production scale.
Biosynth, a supplier of critical raw materials to the life science industry, announced that it has acquired VIO Chemicals, a Zurich-based company with leading chemical R&D expertise and a global network of large-scale manufacturing partners.
The acquisition will expand Biosynth’s ability to secure its customers’ supply chains by bringing greater flexibility in scales for complex chemical manufacturing, with expertise across carbohydrates, nucleosides, intermediates, and specialty excipients, among others.
CEO and President of Biosynth, Urs Spitz, was pleased to welcome Biosynth’s long-standing collaborator. “VIO Chemicals has a long standing relationship with Biosynth and is an excellent addition to our flagship Complex Chemicals division. We know that our customers want to stay working with us as their needs develop, so being able to offer flexibility and scope for greater scales of production, into the many metric tons, is an important part of that.”
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Trocar

Excessive fluid consumption: habit or hormonal disorder? - Which test provides a reliable diagnosis?

Molecular switch may serve as new target point for cancer and diabetes therapies
HIV/AIDS long-term costs high - and unaffordable to most-affected countries
Part of hagfish slime mystery solved

Effects of chemical mixtures: Neurotoxic effects add up - Study demonstrates for the first time the toxicological relevance of chemical mixtures as they occur in humans

Innovative approach to treat autism spectrum disorders - University of Basel spin-off Translation-X receives Venture Kick funding
